A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients

Exogenous arginine is required for growth in some argininosuccinate synthetase (ASS)-deficient cancers. Arginine deiminase (ADI) inhibits growth in various ASS-deficient cancers by depleting arginine. The efficacy of pegylated ADI (ADI-PEG20) in relapsed/refractory/poor-risk acute myeloid leukemia (...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Sci Rep
Egile Nagusiak: Tsai, Hui-Jen, Jiang, Shih Sheng, Hung, Wen-Chun, Borthakur, Gautam, Lin, Sheng-Fung, Pemmaraju, Naveen, Jabbour, Elias, Bomalaski, John S., Chen, Ya-Ping, Hsiao, Hui-Hua, Wang, Ming-Chung, Kuo, Ching-Yuan, Chang, Hung, Yeh, Su-Peng, Cortes, Jorge, Chen, Li-Tzong, Chen, Tsai-Yun
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5595917/
https://ncbi.nlm.nih.gov/pubmed/28900115
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-10542-4
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak